Literature DB >> 20885403

Roflumilast.

Leonardo M Fabbri, Bianca Beghé, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20885403     DOI： 10.1038/nrd3276

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  16 in total

Review 1.  Emerging pharmacotherapies for COPD.

Authors:  Peter J Barnes
Journal:  Chest       Date:  2008-12       Impact factor: 9.410

2.  Medication adherence in COPD: what have we learned?

Authors:  MeiLan K Han
Journal:  Thorax       Date:  2009-11       Impact factor: 9.139

3.  Chronic obstructive pulmonary disease phenotypes: the future of COPD.

Authors:  MeiLan K Han; Alvar Agusti; Peter M Calverley; Bartolome R Celli; Gerard Criner; Jeffrey L Curtis; Leonardo M Fabbri; Jonathan G Goldin; Paul W Jones; William Macnee; Barry J Make; Klaus F Rabe; Stephen I Rennard; Frank C Sciurba; Edwin K Silverman; Jørgen Vestbo; George R Washko; Emiel F M Wouters; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

4.  In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

Authors:  D S Bundschuh; M Eltze; J Barsig; L Wollin; A Hatzelmann; R Beume
Journal:  J Pharmacol Exp Ther       Date:  2001-04       Impact factor: 4.030

Review 5.  Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

Authors:  Brian J Lipworth
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

6.  Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.

Authors:  Diana C Grootendorst; Stefanie A Gauw; Renate M Verhoosel; Peter J Sterk; Jeannette J Hospers; Dirk Bredenbröker; Thomas D Bethke; Pieter S Hiemstra; Klaus F Rabe
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

7.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

Authors:  Leonardo M Fabbri; Peter M A Calverley; José Luis Izquierdo-Alonso; Daniela S Bundschuh; Manja Brose; Fernando J Martinez; Klaus F Rabe
Journal:  Lancet       Date:  2009-08-29       Impact factor: 79.321

8.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

Authors:  Peter M A Calverley; Klaus F Rabe; Udo-Michael Goehring; Søren Kristiansen; Leonardo M Fabbri; Fernando J Martinez
Journal:  Lancet       Date:  2009-08-29       Impact factor: 79.321

Review 9.  Screening for and early detection of chronic obstructive pulmonary disease.

Authors:  Joan B Soriano; Jan Zielinski; David Price
Journal:  Lancet       Date:  2009-08-29       Impact factor: 79.321

10.  Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.

Authors:  Peter M A Calverley; Fernando Sanchez-Toril; Andrew McIvor; Peter Teichmann; Dirk Bredenbroeker; Leonardo M Fabbri
Journal:  Am J Respir Crit Care Med       Date:  2007-04-26       Impact factor: 21.405
View more
  9 in total

1.  Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.

Authors:  Lei Wang; Jun Yang; Lei Guo; Dale Uyeminami; Hua Dong; Bruce D Hammock; Kent E Pinkerton
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

2.  Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice.

Authors:  Hongfang Feng; Jiajia Chen; Haitao Wang; Yufang Cheng; Zhengqiang Zou; Qiuping Zhong; Jiangping Xu
Journal:  Lab Invest       Date:  2017-06-26       Impact factor: 5.662

3.  Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.

Authors:  Ying Tan; Amanda A Watkins; Benjamin B Freeman; John A Meyers; Ian R Rifkin; Adam Lerner
Journal:  J Immunol       Date:  2015-01-01       Impact factor: 5.422

4.  Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.

Authors:  Miriam Wittmann; Philip S Helliwell
Journal:  Dermatol Ther (Heidelb)       Date:  2013-04-27

5.  Clinical highlights from the 2011 ERS Congress in Amsterdam.

Authors:  Martijn A Spruit; Niels H Chavannes; Felix J F Herth; Venerino Poletti; Sebastian Ley; Otto C Burghuber; Enrico Clini; Vincent Cottin
Journal:  Eur Respir J       Date:  2012-03-09       Impact factor: 16.671

6.  Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).

Authors:  Ryan T Cameron; Ryan G Coleman; Jon P Day; Krishna C Yalla; Miles D Houslay; David R Adams; Brian K Shoichet; George S Baillie
Journal:  Biochem Pharmacol       Date:  2013-03-05       Impact factor: 5.858

7.  LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing.

Authors:  Sophie Seehase; Hans-Dieter Lauenstein; Christina Schlumbohm; Simone Switalla; Vanessa Neuhaus; Christine Förster; Hans-Gerd Fieguth; Olaf Pfennig; Eberhard Fuchs; Franz-Josef Kaup; Martina Bleyer; Jens M Hohlfeld; Armin Braun; Katherina Sewald; Sascha Knauf
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

8.  Psiguajadials A-K: Unusual Psidium Meroterpenoids as Phosphodiesterase-4 Inhibitors from the Leaves of Psidium guajava.

Authors:  Gui-Hua Tang; Zhen Dong; Yan-Qiong Guo; Zhong-Bin Cheng; Chu-Jun Zhou; Sheng Yin
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

9.  Ligustrazine Inhibits Lung Phosphodiesterase Activity in a Rat Model of Allergic Asthma.

Authors:  Yajuan Wang; Huizhi Zhu; Jiabing Tong; Zegeng Li
Journal:  Comput Math Methods Med       Date:  2022-01-10       Impact factor: 2.238
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.